Table 2 .
Correlations between AAPR and clinicopathological characteristics in the training cohort.
| Characteristics | AAPR < 0.583 (n = 233) | AAPR ≥ 0.583 (n = 313) | p-value |
|---|---|---|---|
| Age (y) | <0.001 | ||
| <50 | 82 (35.2) | 221 (70.6) | |
| ≥50 | 151 (64.8) | 92 (29.4) | |
| Menopause | <0.001 | ||
| Yes | 133 (57.1) | 79 (25.2) | |
| No | 100 (42.9) | 234 (74.8) | |
| Chemotherapy cycles | 0.924 | ||
| 3 | 8 (3.4) | 9 (2.9) | |
| 4 | 208 (89.3) | 280 (89.5) | |
| 5-8 | 17 (7.3) | 24 (7.7) | |
| Histological type | 0.007 | ||
| Ductal | 219 (94.0) | 304 (97.1) | |
| Lobular | 2 (0.9) | 6 (1.9) | |
| Others | 12 (5.2) | 3 (1.0) | |
| Tumor size | 0.188 | ||
| T1 | 23 (9.9) | 39 (12.5) | |
| T2 | 169 (72.5) | 204 (65.2) | |
| T3 | 41 (17.6) | 70 (22.4) | |
| Clinical nodal status | 0.960 | ||
| Negative | 100 (42.9) | 135 (43.1) | |
| Positive | 133 (57.1) | 178 (56.9) | |
| Histological Grade | 0.189 | ||
| I | 21 (9.0) | 16 (5.1) | |
| II | 171 (73.4) | 236 (75.4) | |
| III | 41 (17.6) | 61 (19.5) | |
| ER | 0.277 | ||
| Negative | 94 (40.3) | 112 (35.8) | |
| Positive | 139 (59.7) | 201 (64.2) | |
| PR | 0.260 | ||
| Negative | 126 (54.1) | 154 (49.2) | |
| Positive | 107 (45.9) | 159 (50.8) | |
| HER2 status | 0.396 | ||
| Negative | 127 (54.5) | 182 (58.1) | |
| Positive | 106 (45.5) | 131 (41.9) | |
| Ki67 expression (%) | 0.608 | ||
| <14 | 74 (31.8) | 93 (29.7) | |
| ≥14 | 159 (68.2) | 220 (70.3) | |
| Molecular subtypes | 0.045 | ||
| Luminal | 97 (41.6) | 133 (42.5) | |
| Luminal/HER2 | 45 (19.3) | 78 (24.9) | |
| HER2 | 61 (26.2) | 53 (16.9) | |
| TNBC | 30 (12.9) | 49 (15.7) | |
| Response evaluation | 0.030 | ||
| pCR | 23 (9.9) | 51 (16.3) | |
| Non-pCR | 210 (90.1) | 262 (83.7) |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2; AAPR, albumin-to-alkaline phosphatase ratio; pCR, pathologic complete response.